High-Risk Resected Melanoma
Source: The Asco Post, August 2023
In a retrospective cohort study reported in JAMA Network Open, Goodman et al found that patients receiving adjuvant PD-1 inhibitor therapy for high-risk resected melanoma often had chronic immune-related adverse events, with some persisting over long-term follow-up.
Study Details
The study included data from patients who received PD-1 inhibitor therapy for advanced and metastatic melanoma between 2015 and 2022 at six institutions in the United States and Australia who had ? 18 months of follow-up after treatment cessation.
Key Findings
The range of follow-up was 18.2 to 70.4 months after PD-1 inhibitor treatment cessation.